What is HC Wainwright’s Estimate for LENZ Q1 Earnings?

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of LENZ Therapeutics in a research note issued on Thursday, March 20th. HC Wainwright analyst M. Caufield expects that the company will post earnings per share of ($0.52) for the quarter. The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($2.18) per share. HC Wainwright also issued estimates for LENZ Therapeutics’ Q3 2025 earnings at ($0.73) EPS.

LENZ Therapeutics (NASDAQ:LENZ) last announced its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.04).

LENZ has been the topic of several other reports. Citigroup increased their price target on shares of LENZ Therapeutics from $44.00 to $47.00 and gave the company a “buy” rating in a report on Thursday. TD Cowen assumed coverage on LENZ Therapeutics in a research report on Tuesday, March 18th. They set a “buy” rating and a $60.00 target price for the company. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, LENZ Therapeutics currently has a consensus rating of “Buy” and an average price target of $41.67.

LENZ Therapeutics Trading Up 0.7 %

LENZ opened at $26.49 on Friday. The stock has a market cap of $728.50 million, a PE ratio of -5.55 and a beta of 0.58. The stock’s fifty day simple moving average is $24.15 and its 200 day simple moving average is $27.06. LENZ Therapeutics has a 1-year low of $14.42 and a 1-year high of $38.93.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in shares of LENZ Therapeutics by 5.3% during the fourth quarter. Vanguard Group Inc. now owns 1,178,447 shares of the company’s stock worth $34,022,000 after buying an additional 59,630 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in LENZ Therapeutics by 83.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 822,957 shares of the company’s stock worth $23,760,000 after buying an additional 374,326 shares during the last quarter. Paradigm Biocapital Advisors LP acquired a new position in shares of LENZ Therapeutics in the 4th quarter valued at about $22,243,000. State Street Corp lifted its stake in LENZ Therapeutics by 18.7% in the third quarter. State Street Corp now owns 289,154 shares of the company’s stock valued at $6,865,000 after buying an additional 45,600 shares during the period. Finally, Alyeska Investment Group L.P. lifted its position in shares of LENZ Therapeutics by 16.4% during the 4th quarter. Alyeska Investment Group L.P. now owns 142,113 shares of the company’s stock valued at $4,103,000 after acquiring an additional 20,000 shares during the period. Institutional investors own 54.32% of the company’s stock.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.